561 related articles for article (PubMed ID: 20877357)
41. Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?
El-Deiry WS; Taylor B; Neal JW
Am Soc Clin Oncol Educ Book; 2017; 37():e8-e15. PubMed ID: 28746017
[TBL] [Abstract][Full Text] [Related]
42. Why Tumor Genetic Heterogeneity May Require Rethinking Cancer Genesis and Treatment.
Gottlieb B; Trifiro M; Batist G
Trends Cancer; 2021 May; 7(5):400-409. PubMed ID: 33243702
[TBL] [Abstract][Full Text] [Related]
43. MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer.
Cipponi A; Goode DL; Bedo J; McCabe MJ; Pajic M; Croucher DR; Rajal AG; Junankar SR; Saunders DN; Lobachevsky P; Papenfuss AT; Nessem D; Nobis M; Warren SC; Timpson P; Cowley M; Vargas AC; Qiu MR; Generali DG; Keerthikumar S; Nguyen U; Corcoran NM; Long GV; Blay JY; Thomas DM
Science; 2020 Jun; 368(6495):1127-1131. PubMed ID: 32499442
[TBL] [Abstract][Full Text] [Related]
44. Spatial and temporal cancer evolution: causes and consequences of tumour diversity.
Hiley CT; Swanton C
Clin Med (Lond); 2014 Dec; 14 Suppl 6():s33-7. PubMed ID: 25468916
[TBL] [Abstract][Full Text] [Related]
45. Harnessing Tumor Evolution to Circumvent Resistance.
Pogrebniak KL; Curtis C
Trends Genet; 2018 Aug; 34(8):639-651. PubMed ID: 29903534
[TBL] [Abstract][Full Text] [Related]
46. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
47. Recent advances in apoptosis, mitochondria and drug resistance in cancer cells.
Indran IR; Tufo G; Pervaiz S; Brenner C
Biochim Biophys Acta; 2011 Jun; 1807(6):735-45. PubMed ID: 21453675
[TBL] [Abstract][Full Text] [Related]
48. Intratumor heterogeneity: seeing the wood for the trees.
Yap TA; Gerlinger M; Futreal PA; Pusztai L; Swanton C
Sci Transl Med; 2012 Mar; 4(127):127ps10. PubMed ID: 22461637
[TBL] [Abstract][Full Text] [Related]
49. Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms.
Hughes D; Andersson DI
Nat Rev Genet; 2015 Aug; 16(8):459-71. PubMed ID: 26149714
[TBL] [Abstract][Full Text] [Related]
50. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.
Wilting RH; Dannenberg JH
Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866
[TBL] [Abstract][Full Text] [Related]
51. Clonal cooperativity in heterogenous cancers.
Zhou H; Neelakantan D; Ford HL
Semin Cell Dev Biol; 2017 Apr; 64():79-89. PubMed ID: 27582427
[TBL] [Abstract][Full Text] [Related]
52. Genomic evolution of cancer models: perils and opportunities.
Ben-David U; Beroukhim R; Golub TR
Nat Rev Cancer; 2019 Feb; 19(2):97-109. PubMed ID: 30578414
[TBL] [Abstract][Full Text] [Related]
53. A new model isolates glioblastoma clonal interactions and reveals unexpected modes for regulating motility, proliferation, and drug resistance.
Davis JB; Krishna SS; Abi Jomaa R; Duong CT; Espina V; Liotta LA; Mueller C
Sci Rep; 2019 Nov; 9(1):17380. PubMed ID: 31758030
[TBL] [Abstract][Full Text] [Related]
54. Modeling Tumor Clonal Evolution for Drug Combinations Design.
Zhao B; Hemann MT; Lauffenburger DA
Trends Cancer; 2016 Mar; 2(3):144-158. PubMed ID: 28435907
[TBL] [Abstract][Full Text] [Related]
55. An evolutionary perspective on the systems of adaptive immunity.
Müller V; de Boer RJ; Bonhoeffer S; Szathmáry E
Biol Rev Camb Philos Soc; 2018 Feb; 93(1):505-528. PubMed ID: 28745003
[TBL] [Abstract][Full Text] [Related]
56. Understanding resistance to targeted cancer drugs through loss of function genetic screens.
Berns K; Bernards R
Drug Resist Updat; 2012 Oct; 15(5-6):268-75. PubMed ID: 23142522
[TBL] [Abstract][Full Text] [Related]
57. Understanding the Cause and Consequence of Tumor Heterogeneity.
Khatib S; Pomyen Y; Dang H; Wang XW
Trends Cancer; 2020 Apr; 6(4):267-271. PubMed ID: 32209440
[TBL] [Abstract][Full Text] [Related]
58. Optimizing Cancer Treatment Using Game Theory: A Review.
Stanková K; Brown JS; Dalton WS; Gatenby RA
JAMA Oncol; 2019 Jan; 5(1):96-103. PubMed ID: 30098166
[TBL] [Abstract][Full Text] [Related]
59. The translational potential of circulating tumour DNA in oncology.
Patel KM; Tsui DW
Clin Biochem; 2015 Oct; 48(15):957-61. PubMed ID: 25889059
[TBL] [Abstract][Full Text] [Related]
60. Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells.
Saeed K; Ojamies P; Pellinen T; Eldfors S; Turkki R; Lundin J; Järvinen P; Nisen H; Taari K; Af Hällström TM; Rannikko A; Mirtti T; Kallioniemi O; Östling P
Int J Cancer; 2019 Mar; 144(6):1356-1366. PubMed ID: 30125350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
